TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/09/2023
Voltar para busca
Dado oficial do USPTO
K
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
21/09/2023
Tipo de marca
Mista
Classes Nice
5
Data de depósito
02/03/2018
Data de registro
26/10/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/10/2021
Última transação
21/09/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/08/2021
Primeiro uso no comércio
01/08/2021
Código do desenho
3
Tipo de titular
03
Localização do titular
New York City, NY
Examinador
MAYES, LAURIE ANN
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized dark blue ribbon shape oriented horizontally with the legs of the ribbon extending outwards toward the right edge of the ribbon, with a stylized light blue bar bisecting the top part of the ribbon, creating a white diamond shape, with the two stylized geometric shapes together comprising a stylized letter "K".
Titulares e representantes
Titulares
KNACK PHARMACEUTICALS, INC.
Representantes
Tomas Maria Casalins Fox Horan & Camerini LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of epilepsy disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of skin diseasesallergies and rheumatic disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of Alzheimer; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for the treatment of bone disorders and bone diseases; Pharmaceutical preparations for the treatment of toxic effects; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for the prevention and treatment of hormone disorders and deficiencies; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the treatment and prevention of metabolicendocrine and kidney related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of nausea and vomiting; Pharmaceutical preparations for the prevention and treatment of aids-related disorders and diseases; Pharmaceutical preparations for treatment and prevention of viral and bacterial infections; Pharmaceutical preparationsinjectable contraceptives
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/09/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/09/2023
CCON
COUNTERCLAIM OPP. NO. 999999
11/07/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/11/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
17/11/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/11/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/11/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
26/10/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
18/09/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
17/09/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
17/09/2021
IUAF
USE AMENDMENT FILED
10/09/2021
EISU
TEAS STATEMENT OF USE RECEIVED
10/09/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
17/03/2021
EX5G
SOU EXTENSION 5 GRANTED
16/03/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
16/03/2021
EXT5
SOU EXTENSION 5 FILED
02/03/2021
EEXT
SOU TEAS EXTENSION RECEIVED
02/03/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/08/2020
EX4G
SOU EXTENSION 4 GRANTED
06/08/2020
EXT4
SOU EXTENSION 4 FILED
06/08/2020
EEXT
SOU TEAS EXTENSION RECEIVED
06/08/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/03/2020
EX3G
SOU EXTENSION 3 GRANTED
05/03/2020
EXT3
SOU EXTENSION 3 FILED
05/03/2020
EEXT
SOU TEAS EXTENSION RECEIVED
05/03/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
30/08/2019
EX2G
SOU EXTENSION 2 GRANTED
28/08/2019
EXT2
SOU EXTENSION 2 FILED
28/08/2019
EEXT
SOU TEAS EXTENSION RECEIVED
28/08/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/03/2019
EX1G
SOU EXTENSION 1 GRANTED
04/03/2019
EXT1
SOU EXTENSION 1 FILED
04/03/2019
EEXT
SOU TEAS EXTENSION RECEIVED
04/03/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/09/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/07/2018
PUBO
PUBLISHED FOR OPPOSITION
17/07/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/06/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/06/2018
DOCK
ASSIGNED TO EXAMINER
13/06/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/03/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/03/2018
NWAP
NEW APPLICATION ENTERED
06/03/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace K ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.